alpha-1 receptor Inhibitors
1 drugsAbout alpha-1 receptor
The alpha-1 receptor is an adrenergic receptor subtype that binds catecholamines like norepinephrine and epinephrine, initiating intracellular signaling. Found throughout the body, these receptors mediate diverse physiological processes.
While no genetic evidence directly links alpha-1 receptors to specific diseases, their role in biological pathways suggests therapeutic potential through activity modulation.
Currently, one FDA-approved drug, DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, targets this receptor as a small molecule.
Top alpha-1 receptor Drugs
Pfizer is the only company with an approved drug targeting the alpha-1 receptor.
The limited number of players suggests a low competitive intensity and potential for market entry.
alpha-1 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha-1 receptor, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer a competitive advantage.
alpha-1 receptor Clinical Trials 27 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alpha-1 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 5 | 1 | 0 | 83% |
| Phase 2 | 9 | 4 | 3 | 1 | 57% |
| Phase 3 | 4 | 2 | 1 | 1 | 67% |
| Phase 4 | 8 | 4 | 0 | 4 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha-1 receptor Drug Approval Timeline (1983 - 1983)
Shock
The first and only drug was approved in 1983, with no new approvals since.
The absence of recent approvals indicates a potential for innovation and new therapeutic approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 22 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alpha-1 receptor. A trial counts if an approved drug acting on alpha-1 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.